Skip to main content

Table 2 Objective response in the study population

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Variables, n (%) Alectinib (n = 41)a Ceritinib (n = 22)
Response
 No. of patients 30 11
 % (95% CI) 73.2 (57.1–85.8) 50.0 (28.2–71.8)#
Complete response-- no. (%) 1 (2.4) 0
Partial response--no. (%) 29 (70.8) 11 (50.0)
Stable disease--no. (%) 6 (14.6) 6 (27.3)
Progression disease--no. (%) 5 (12.2) 5 (22.7)
  1. aNot evaluable in 2 patients. # p = 0.096 for the comparison between alectinib and ceritinib